Due to its unusually long duration, extreme potency, and compulsive nature, it is strongly discouraged to abuse this substance in high doses, multiple days in a row, or in combination with other drugs known to increase the risk of psychosis. Please see this section for more details.
|Summary sheet: MDPV|
|Molecular structure of MDPV|
|Common names||MDPV, "Bath Salts", NRG-1|
|Psychoactive class||Stimulant, Entactogen|
|Chemical class||Cathinone / Pyrrolidine|
|Routes of Administration|
3,4-Methylenedioxypyrovalerone (also known as MDPV, NRG-1, and imprecisely as Bath Salts, among many others) is a novel, extremely potent synthetic stimulant substance of the cathinone and pyrrolidine chemical classes that produces states of extreme stimulant euphoria, disinhibition, and sexual arousal when administered. MDPV is thought to act primarily as as a norepinephrine-dopamine reuptake inhibitor (NDRI) and possesses powerful euphoric stimulant qualities. It was first developed in the 1960s by a team at Boehringer Ingelheim.
MDPV remained an obscure stimulant until around 2004, when it was reportedly first made available to the public as a designer drug. Products labeled as "bath salts" containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing strategy of Spice and K2 as incense.
Historical reports show records of the preparation of MDPV for potential use as a CNS stimulant. It was claimed to have potential to be an alternative for racemic amphetamine and, although showing some desirable qualities such as reduced toxicity as compared to amphetamine, MDPV was chosen to not be developed as a medicinal drug.
Several incidents of psychological and physical harm have been attributed to the use of MDPV, including an unusually large number of fatalities. A total of 107 non-fatal intoxications and 99 analytically confirmed deaths related to MDPV between September 2009 and August 2013 were reported by nine European countries.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
MDPV, or 3,4-Methylenedioxypyrovalerone, is a synthetic stimulant of the cathinone and pyrrolidine classes. MDPV is the 3,4-methylenedioxy ring-substituted analog of the compound a-PVP, developed in the 1960s, which has been used for the treatment of chronic fatigue and as an anorectic, but caused problems of abuse and dependence. However, despite some shared structural features, the effects of MDPV bear little resemblance to other methylenedioxy phenylalkylamine derivatives such as 3,4-methylenedioxy-N-methylamphetamine (MDMA), instead producing primarily classical stimulant effects with only mild entactogenic qualities.
MDPV is thought to act primarily as a potent norepinephrine-dopamine reuptake inhibitor. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two catecholamine neurotransmitters in the synaptic cleft, or gap between neurons. The result of this inhibition is an enhanced and prolonged concentration and resulting post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. Serotonin also plays a role, although to a much lesser degree. This sudden increase in neurotransmitter concentration in the brain is thought to be responsible for the high that MDPV produces. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like cocaine or methylphenidate than amphetamine in method of action. In contrast, amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.
- Stamina enhancement
- Abnormal heartbeat
- Increased heart rate - Higher doses of MDPV can create a significant and often dangerous increase in heart rate and blood pressure.
- Muscle contractions
- Muscle spasms
- Appetite suppression
- Gustatory hallucinations
- Diarrhea - Some users have reported experiencing diarrhea while under the influence of MDPV, although this seems to be a relatively uncommon effect.
- Nausea - Some users have reported experiencing nausea while under the influence of MDPV, although this seems to be a relatively uncommon effect.
- Restless leg syndrome
The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects commonly include:
- Cognitive fatigue
- Motivation suppression
- Thought deceleration
The general cognitive effects of MDPV can be described as being similar to those of other typical stimulants. At common dosages, the MDPV high is described as being euphoric and slightly empatheogenic in its effects, causing increased motivation, sociability, sexual desire and concentration. Higher doses of MDPV, however, can intensify numerous negative effects such as anxiety and disorganized thoughts; at extremely high doses or continued use, delusions and psychosis become likely.
- Cognitive euphoria
- Compulsive redosing - MDPV is extremely potent in this effect; it been shown to sometimes cause users to redose even without planning to do so.
- Confusion - This effect is intensified at higher doses.
- Creativity enhancement
- Delusions - This effect can also manifest with high doses.
- Ego inflation
- Empathy, love, and sociability enhancement - MDPV's effects in this regard are similar to, but weaker than, those of MDMA.
- Focus enhancement
- Increased libido
- Motivation enhancement
- Stamina enhancement
- Psychosis - High doses of MDPV have been known to induce states of psychosis at a more frequent rate than most other stimulants.
- Time distortion - This can be described as the experience of time speeding up and passing much quicker than it usually would when sober.
- Thought acceleration
- Thought organization - Mainly observed with low to common doses.
- Thought disorganization - This effect manifests and is also intensified with higher doses.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As such, it may contain incomplete or even dangerously wrong information. You can help by expanding upon or correcting it.
MDPV has a relatively short history of human use, with very few mentions concerning the use thereof before 2004. Although once considered a potential alternative to existing stimulants with a lower risk for toxicity, human MDPV administration has not been extensively studied in a clinical setting for many decades. Despite this, several recent studies on cases of persisting psychosis caused by chronic use of MDPV show promising rates of recovery among individuals who are treated with certain antipsychotics and first-line antihistamines. There is currently no conclusive data concerning the neurotoxicity of MDPV in the human brain.
Anecdotal evidence from those who have tried MDPV in the community suggest that there are no negative health effects associated with the substance if simply taken at low doses by itself and when used sparingly (but nothing can be completely guaranteed).
Data taken from in-vitro and in-vivo studies have indicated that MDPV shares similar properties to methamphetamine and cocaine; in fact, MDPV is more potent than these two stimulants in a number of varying ways. The over-excitation of dopamine and noradrenaline caused by MDPV use, combined with MDPV's potential inability to create compensatory serotonergic activity, sets the stage for a number of hostile and psychotic reactions to the drug. These hostile tendencies have been witnessed in emergency response situations, and have also seen wide television coverage in the past, after an individual under the influence of MDPV viciously assaulted an innocent bystander. It is uncertain if the individual had any pre-existing mental disorders or if he was under the influence of any other drugs.Template:Citation neeeded
The exact lethal dosage of MDPV is unknown and no formal studies have been carried out in humans. For sake of reference, one report placed the lethal dosage for a 39 year old male at 0.4 micrograms per millilitre or greater following the results of a post mortem, but this data is far too individually unique and the variables simply too diverse to derive any kind of meaningful information from it. MDPV may be quantified in blood, plasma or urine by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry to confirm a diagnosis of poisoning in hospitalized patients or to provide evidence in a medicolegal death investigation. Blood or plasma MDPV concentrations are expected to be in a range of 10–50 μg/L in persons using the drug recreationally, >50 μg/L in intoxicated patients, and >300 μg/L in victims of acute overdose.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
More so than other stimulants, the chronic use of MDPV can be considered moderately to highly addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. Addiction is a serious risk among users of MDPV as it easily causes compulsive redosing and causes highly unpleasant comedown symptoms.
User reports indicate that chronic abuse or single exposure overdose of MDPV can potentially lead to psychosis more readily than the vast majority of stimulants. Psychotic symptoms from MDPV can include hearing voices, visual hallucinations, urges to harm oneself, severe anxiety, mania, grandiosity, paranoid delusions, confusion, increased aggression, and irritability.
Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
- Stimulants - MDPV can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
- 25x-NBOMe - Both the NBOMe series and this compound induce powerful stimulation and their interaction may cause severe side effects. These can include thought loops, seizures, increased blood pressure, vasoconstriction, increased heart rate, and heart failure (in extreme cases).
- Alcohol - It is dangerous to combine alcohol, a depressant, with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of alcohol which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of alcohol will be significantly increased, leading to intensified disinhibition as well as respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
- DXM - This combination may cause increased heart rate and panic attacks.
- MXE - Increased heart rate and blood pressure may occur.
- Tramadol - This combination can increase the risk of seizures.
- MDMA - The neurotoxic effects of MDMA may be increased when combined with amphetamine and other stimulants.
- MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, 2C-T-2, 2C-T-7, αMT, and some antidepressants.
- Cocaine - This combination may increase strain on the heart.
- Australia - In Western Australia, MDPV has been banned under the Poisons Act 1964, having been included in Appendix A Schedule 9 of the Poisons Act 1964 as from February 11, 2012. The Director of Public Prosecutions for Western Australia announced that anyone intending to sell or supply MDPV faces a maximum $100,000 fine or 25 years in jail. Users face a $2000 fine or two years' jail. Therefore, anyone caught with MDPV can be charged with possession, selling, supplying or intent to sell or supply.
- Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- Canada - On June 5, 2012 the Canadian Health Minister Leona Aglukkaq announced that MDPV would be listed on Schedule I of the Controlled Drugs and Substances Act, which was passed into law on September 26, 2012.
- Finland - MDPV is specifically listed as a controlled substance in Finland (listed appendix IV substance as of June 28, 2010), Denmark]] and Sweden. In Sweden a 33-year-old man has been sentenced to six years in prison by an appellate court, Hovrätt, for possession of 250 grams of MDPV that had been acquired prior to criminalization.
- United Kingdom - In the UK, following the Advisory Council on the Misuse of Drugs|ACMD's report on substituted cathinone derivatives, MDPV is a Class B drug under The Misuse of Drugs Act 1971 (Amendment) Order 2010, making it illegal to sell, buy, or possess without a license.
- United States - On October 21, 2011, MDPV became a DEA federally scheduled drug. The DEA issued a temporary one-year ban on MDPV, classifying it as a schedule I substance. On December 8, 2011, under the Synthetic Drug Control Act, the US House of Representatives voted to ban MDPV and a variety of other synthetic drugs which had been sold legally in stores.
- Responsible use
- Research chemical
- Substituted cathinone
- Substituted pyrrolidine
- US Patent 3478050 - 1-(3',4'-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1) | https://www.google.com/patents/US3478050
- MDPV Summary | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1
- EMCDDA–Europol Joint Report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone) | http://www.emcdda.europa.eu/system/files/publications/819/TDAS14001ENN_466653.pdf
- US Patent 3478050 - 1-(3',4'-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1) | https://www.google.com/patents/US3478050
- MDPV | https://wiki.tripsit.me/wiki/MDPV
- InnerExplorer. "Personal Research Comedown Guide: An Experience with MDPV (ID 98601)". Erowid.org. Feb 21, 2013. erowid.org/exp/98601 | https://erowid.org/experiences/exp.php?ID=98601
- Trippy. "Seemingly Real Paranoid Hallucination Hell: An Experience with MDPV (ID 91741)". Erowid.org. Jun 30, 2011. erowid.org/exp/91741 | https://erowid.org/experiences/exp.php?ID=91741
- Some Guy. "Psychosis: An Experience with MDPV (ID 78382)". Erowid.org. Mar 22, 2010. erowid.org/exp/78382 | https://www.erowid.org/experiences/exp.php?ID=78382
- Studies concerning MDPV hospitalization, pages 19 to 25. | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1
- MDPV In-vivo statistics | http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1
- Disposition of toxic drugs and chemicals in man | isbn = 978-0-9626523-9-4
- Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
- Emerging drug, MDPV banned in WA | https://www.mediastatements.wa.gov.au/Pages/Barnett/2012/02/Emerging-drug,-MDPV-banned-in-WA.aspx
- 'Bath salts' drug ingredient banned in Canada | http://www.cbc.ca/news/politics/bath-salts-drug-ingredient-banned-in-canada-1.1174926
- Finlex: huumausaineina pidettävistä aineista, valmisteista ja kasveista annetun valtioneuvoston asetuksen liitteen IV muuttamisesta | http://www.finlex.fi/fi/laki/alkup/2010/20100596
- Hovrätten skärper straff i MDPV-dom | http://www.nt.se/nyheter/?articleid=6057819
- A change to the Misuse of Drugs Act 1971 : Control of mephedrone and other cathinone derivatives | http://webarchive.nationalarchives.gov.uk/20130125102358/http://www.homeoffice.gov.uk/about-us/corporate-publications-strategy/home-office-circulars/circulars-2010/010-2010/
- House Votes to Ban 'Spice,' 'Bath Salts' ABC News | http://abcnews.go.com/Blotter/house-votes-ban-fake-marijuana-fake-cocaine/story?id=15116235